Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $237.5 million. The company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $2.05 per share was 57.8% above analysts’ consensus estimates.

Is now the time to buy ANI Pharmaceuticals? Find out by accessing our full research report, it’s free.

“We delivered a strong first quarter, generating $237.5 million in revenue and $63.0 million in adjusted non-GAAP EBITDA, with solid performance across all business units,” said Nikhil Lalwani, President and CEO of ANI.

Company Overview

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, ANI Pharmaceuticals’s 34.1% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. ANI Pharmaceuticals’s annualized revenue growth of 33.6% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong.

This quarter, ANI Pharmaceuticals reported robust year-on-year revenue growth of 20.5%, and its $237.5 million of revenue topped Wall Street estimates by 14%.

Looking ahead, sell-side analysts expect revenue to grow 24.4% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is admirable and suggests the market is baking in success for its products and services.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

ANI Pharmaceuticals has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 24.5%.

Analyzing the trend in its profitability, ANI Pharmaceuticals’s adjusted operating margin rose by 7.3 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company’s margin has decreased by 2.1 percentage points on a two-year basis. If ANI Pharmaceuticals wants to pass our bar, it must prove it can expand its profitability consistently.

In Q1, ANI Pharmaceuticals generated an adjusted operating margin profit margin of 20.7%, down 5.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

ANI Pharmaceuticals’s EPS grew at an astounding 18.6% compounded annual growth rate over the last five years. Despite its adjusted operating margin improvement during that time, this performance was lower than its 34.1% annualized revenue growth, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.

Diving into ANI Pharmaceuticals’s quality of earnings can give us a better understanding of its performance. A five-year view shows ANI Pharmaceuticals has diluted its shareholders, growing its share count by 79.3%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, ANI Pharmaceuticals reported adjusted EPS of $2.05, up from $1.70 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. We also like to analyze expected EPS growth based on Wall Street analysts’ consensus projections, but there is insufficient data.

Key Takeaways from ANI Pharmaceuticals’s Q1 Results

It was good to see ANI Pharmaceuticals beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this quarter featured some important positives. The stock traded up 8.3% to $90.85 immediately following the results.

Indeed, ANI Pharmaceuticals had a rock-solid quarterly earnings result, but is this stock a good investment here? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).